Endometrial Hyperplasia

Endometrial hyperplasia (EH) is a condition characterized by the abnormal proliferation of the endometrial glands, resulting in an increased gland-to-stroma ratio compared to proliferative endometrium. It is primarily driven by prolonged estrogen exposure unopposed by progesterone. EH is clinically significant due to its potential for progression to endometrioid adenocarcinoma.

The primary cause is chronic, unopposed estrogen stimulation. This may result from endogenous sources (e.g., polycystic ovary syndrome, obesity, granulosa cell tumors) or exogenous sources (e.g., unopposed estrogen replacement therapy, tamoxifen use). Genetic factors, such as Lynch syndrome (HNPCC) or mutations in the PTEN tumor suppressor gene, significantly increase risk.

In a healthy cycle, estrogen induces endometrial growth, while progesterone triggers shedding. Without progesterone, the endometrium remains in a proliferative state. Molecularly, persistent estrogen leads to mutations in the PTEN gene. Overgrowth leads to structural gland crowding and cytological abnormalities (atypia), which serve as precursors to malignant transformation.

EH is most common in perimenopausal and postmenopausal women. Prevalence estimates vary widely, with higher incidence in industrialized nations, largely due to the association with obesity and metabolic syndrome.

• Obesity (increased peripheral conversion of androgens to estrogen)
• Polycystic Ovary Syndrome (PCOS)
• Nulliparity
• Early menarche or late menopause
• Diabetes mellitus
• Tamoxifen therapy
• Lynch syndrome

A. Early Symptoms

• Intermenstrual bleeding


• Irregular cycles B. Common Symptoms


• Heavy menstrual bleeding (menorrhagia)


• Prolonged menses


• Postmenopausal bleeding C. Advanced Symptoms


• Pelvic pain/pressure


• Anemia symptoms (fatigue, pallor) D. Emergency Symptoms


• Hemodynamic instability due to severe hemorrhage


• Acute severe pelvic pain

Generally unremarkable. Pelvic examination may reveal a normal uterus or, in rare cases, uterine enlargement. Speculum exam confirms the bleeding source (cervix vs. uterine cavity).

A. Clinical Assessment: Thorough history focusing on menstrual patterns and medication use.
B. Laboratory Testing: CBC to assess anemia; hormonal panels (FSH, LH, TSH).
C. Imaging Studies: Transvaginal ultrasound (TVS) for endometrial thickness (ET).
D. Functional Tests: Not applicable.
E. Biopsy Findings: Definitive diagnosis via endometrial biopsy (EMB).
F. Genetic Testing: Microsatellite instability (MSI) testing if hereditary cancer syndrome is suspected.
G. Differential Diagnosis: Endometrial polyps, endometrial carcinoma, submucosal leiomyoma.

Test Name: Complete Blood Count (CBC)
Type: Blood Test
Purpose: Assess for anemia from chronic bleeding.
Expected Findings: Low hemoglobin/hematocrit.
Interpretation: Indicates severity of blood loss. Test Name: Progesterone/Estradiol levels
Type: Blood Test
Purpose: Evaluate hormonal imbalance.
Expected Findings: Elevated estrogen/low progesterone.
Interpretation: Confirms state of unopposed estrogen.

• Transvaginal Ultrasound (TVS): Used to measure endometrial thickness. ET > 4–5 mm in postmenopausal women warrants biopsy.
• Hysteroscopy: Gold standard for visualizing the cavity and directed biopsy.

Endometrial cancer (must be ruled out via biopsy), endocervical polyps, atrophy (in postmenopausal women), and intrauterine devices.

• Endometrial carcinoma
• Chronic anemia
• Infertility
• Hemorrhagic complications

A. Lifestyle Modifications: Weight loss to reduce aromatization of estrogen.
B. Preventive Measures: Progestin supplementation during HRT.
C. Medical Treatment

• Progestins (cyclic or continuous): Medroxyprogesterone acetate, Levonorgestrel-releasing IUD.

Good for non-atypical EH; risk of progression is <5%. Atypical hyperplasia has a 25-40% risk of progression to cancer if untreated.

Balanced nutrition, exercise, management of PCOS, and careful administration of estrogen-only hormone replacement therapy (always include progestin).

The following homeopathic remedies have been historically indicated for symptoms associated with Endometrial Hyperplasia. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

🔬 Lab Report Analyzer (Diagnostic Verification)

Upload your laboratory bloodwork PDF or paste your report text to automatically extract markers, detect units, and identify reference range variances related to Endometrial Hyperplasia.